Compare TACT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | LGVN |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 34.0M |
| IPO Year | 1996 | 2021 |
| Metric | TACT | LGVN |
|---|---|---|
| Price | $3.93 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $3.00 |
| AVG Volume (30 Days) | 57.9K | ★ 367.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.88 | 50.76 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $10.36 | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | $55.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.06 | $0.48 |
| 52 Week High | $5.70 | $1.80 |
| Indicator | TACT | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 47.89 |
| Support Level | $3.67 | $0.74 |
| Resistance Level | $4.76 | $0.86 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 80.51 | 62.76 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.